Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) CTO Purchases $19,999.85 in Stock

Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) CTO Meeshanthini Dogan purchased 68,965 shares of the company’s stock in a transaction that occurred on Friday, September 6th. The shares were purchased at an average cost of $0.29 per share, for a total transaction of $19,999.85. Following the completion of the transaction, the chief technology officer now owns 197,310 shares in the company, valued at approximately $57,219.90. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Cardio Diagnostics Price Performance

Shares of NASDAQ CDIO opened at $0.29 on Thursday. The firm’s 50-day moving average price is $0.44 and its two-hundred day moving average price is $0.77. Cardio Diagnostics Holdings, Inc. has a 52-week low of $0.17 and a 52-week high of $3.56.

Cardio Diagnostics (NASDAQ:CDIO) last released its quarterly earnings data on Monday, August 12th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.07. Cardio Diagnostics had a negative return on equity of 312.97% and a negative net margin of 22,358.43%. The business had revenue of $0.01 million during the quarter, compared to analyst estimates of $0.13 million. On average, analysts predict that Cardio Diagnostics Holdings, Inc. will post -0.55 EPS for the current year.

Wall Street Analyst Weigh In

Separately, Benchmark reissued a “speculative buy” rating and set a $2.00 target price on shares of Cardio Diagnostics in a report on Tuesday, August 27th.

Cardio Diagnostics Company Profile

Cardio Diagnostics Holdings, Inc, an artificial intelligence-powered precision cardiovascular medicine company, develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease.